Results: All PSB had vascular channels observed on lCT originating from the abaxial border (mean 3.6, s.d. 0.89), yet in only 63.6% (75/118) were channels observed radiographically. PSB with a higher bone volume fraction (OR 1.08; P = 0.031) and wider channel diameter on lCT (OR 20.67, P = 0.001) were more likely to have vascular channels identified on radiographs. Radiographic channel number (OR 0.96; P = 0.043) and channel size (OR 0.96; P = 0.049) were negatively associated with career placings.
Main limitations: Radiographs of isolated bones avoided the normal superimposition of tissue encountered in the live horse.
Conclusions:
The ability to identify vascular channels radiographically indicates widening of the channels and densification of the PSB. Increased radiographic channel number and size is associated with poorer measures of past performance suggesting that these changes are not desirable. Background: Biomarkers for early identification of musculoskeletal disorders are needed to limit the number of catastrophic injuries in Thoroughbred racehorses. Nuclear magnetic resonance (NMR) metabolomics has high potential for new serum biomarker discovery; however, it has not been applied for investigating musculoskeletal injuries in racehorses.
Objectives: Longitudinal comparison of serum metabolic profiles in horses that sustained musculoskeletal injury and uninjured racehorses.
Study design: Longitudinal retrospective case-control study.
Methods: Serum samples collected from a cohort of 2-year-old Thoroughbred racehorses were used for data acquisition. Serum from one racehorse diagnosed with fetlock synovitis, one with distal acute fracture, and a healthy racehorse, was profiled using NMR spectroscopy at the time of diagnosis, at 2 and 3 months before the injury. All horses were stabled and trained by one trainer and the control horse randomly selected from the cohort. All NMR spectra were collected at 700 MHz 1H frequency and processed using Mnova 12.0.1 (Mestrelab Research).
Results: 60 unique metabolites of 135 identified by NMR in serum samples were assigned and quantified. 12 metabolites observed by NMR were elevated (2-to 12-fold) in injured horses relative to control, including proline, leucine, isoleucine and pyruvate, whose presence in bio-fluids has previously been related to equine joint pathology [1, 2, 3] . Detected compounds are associated with extracellular matrix turnover and energy metabolism. Background: The pathogenesis of osteoarthritis (OA) is not fully understood, with no disease-modifying treatments available. Few studies have used a global approach to stratify the equine synovial fluid proteome according to OA severity. The identification of differentially expressed proteins according to OA severity will aid our understanding of underlying disease pathogenesis, determining markers of early OA to allow timely management interventions and aid in discovering potential therapeutic targets.
Objectives: To identify proteomic markers of equine osteoarthritis.
Study design: Retrospective cross-sectional clinical study.
Methods: Synovial fluid was collected from 47 metacarpophalangeal and metatarsophalangeal joints of racing Thoroughbred horses following euthanasia. Condylar subchondral bone/cartilage sections were histologically assessed using the OARSI modified Mankin scoring system and categorised as mild (n = 16), moderate (n = 19) or severe (n = 12). Synovial fluid was loaded on to ProteoMiner TM equalisation columns to deplete high abundant proteins. Samples were run using liquid chromatography-tandem mass spectrometry on an UltiMate 3000 Nano LC System coupled to a Q Exactive Quadrupole-Orbitrap instrument. Label-free quantification was undertaken with ANOVA values of P<0.05 and altered regulation of >2-fold regarded as significant.
Results: 26 proteins were differentially expressed between severities of OA, involved within various biological pathways, including GTPase activity/binding (tubulin beta chain and guanylate binding protein family number 6), the complement system (complement C1s), cobalamin binding (transcobalamin 2) and cell matrix adhesion (fibrinogen beta and gamma chains).
